カテゴリー： GlobalData, 企業調査

DBV Technologies SA (DBV)：製薬・医療：M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書（DATA904C3329）
◆英語タイトル：DBV Technologies SA (DBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3329
◆発行会社（リサーチ会社）：GlobalData
◆発行日：2018年8月
◆ページ数：57
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥34,500見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥69,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥103,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

 【レポートの概要】

Summary
DBV Technologies SA (DBV) is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets non-invasive epicutaneous delivery technology and products for healthcare markets. Its viaskin technology platform is an electrostatic patch that provides a suitable, self-administered and non-invasive immunotherapy to patients. DBV’s products include Viaskin Peanut for the treatment of peanut allergies; Viaskin Milk for cow’s protein milk allergies; Viaskin Egg for the treatment of egg allergy and Viaskin Plateform, among others. The company works in collaboration with institutes, universities and pharmaceutical companies. It conducts research in existing and new indications. The company operates in the US and France. DBV is headquartered in Montrouge, France.

DBV Technologies SA (DBV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DBV Technologies SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
DBV Technologies SA, Medical Devices Deals, 2012 to YTD 2018 10
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
DBV Technologies SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
DBV Technologies Enters Into Research Agreement With Icahn School of Medicine at Mount Sinai For Viaskin 12
DBV Technologies Enters into Agreement with BioNet-Asia and University of Geneva 14
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 15
DBV Technologies Enters Into Research Agreement With Stallergenes 17
DBV Technologies Exercises Option for R&D Agreement with Stallergenes for Birch Allergy Treatment 18
DBV Technologies Enters Into Research Agreement With Mount Sinai Hospital 19
Equity Offering 20
DBV Technologies Raises USD59.2 Million in Public Offering of Shares 20
DBV Technologies Raises USD91 Million in Private Placement of Shares 22
DBV Technologies Completes Public Offering of American Depositary Shares for USD281.5 Million 24
DBV Technologies Raises USD106.5 Million in Public Offering of Shares 26
DBV Technologies Raises USD34 Million in Private Placement of Shares 28
DBV Technologies Raises USD22.8 Million in Private Placement of Shares 30
DBV Technologies Completes IPO for USD53.6 Million 32
Acquisition 34
Stallergenes Acquires 2% Stake in DBV Technologies 34
DBV Technologies SA – Key Competitors 35
DBV Technologies SA – Key Employees 36
DBV Technologies SA – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Mar 14, 2018: DBV Technologies Reports Full Year 2017 Financial Results 38
Jul 28, 2017: DBV Technologies Reports First Half 2017 Financial Results 39
Mar 15, 2017: DBV Technologies Reports Full Year 2016 Financial Results 40
Corporate Communications 41
Jun 15, 2017: DBV Technologies Announces Appointment of Julie O’Neill to Board of Directors 41
Product News 42
10/12/2017: DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut 42
06/17/2017: DBV Technologies Highlights Poster Presentations on EPIT at the 2017 EAACI Congress 43
Clinical Trials 44
Nov 20, 2017: DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients 44
Nov 14, 2017: DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association 46
Oct 20, 2017: DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age 48
Aug 29, 2017: DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut 50
Aug 02, 2017: DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age 51
Mar 10, 2017: DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children 52
Mar 05, 2017: Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children 53
Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis 55
Other Significant Developments 56
Jul 27, 2018: DBV Technologies Reports June 30, 2018 Cash Position 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
DBV Technologies SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DBV Technologies SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DBV Technologies SA, Deals By Therapy Area, 2012 to YTD 2018 9
DBV Technologies SA, Medical Devices Deals, 2012 to YTD 2018 10
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
DBV Technologies Enters Into Research Agreement With Icahn School of Medicine at Mount Sinai For Viaskin 12
DBV Technologies Enters into Agreement with BioNet-Asia and University of Geneva 14
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 15
DBV Technologies Enters Into Research Agreement With Stallergenes 17
DBV Technologies Exercises Option for R&D Agreement with Stallergenes for Birch Allergy Treatment 18
DBV Technologies Enters Into Research Agreement With Mount Sinai Hospital 19
DBV Technologies Raises USD59.2 Million in Public Offering of Shares 20
DBV Technologies Raises USD91 Million in Private Placement of Shares 22
DBV Technologies Completes Public Offering of American Depositary Shares for USD281.5 Million 24
DBV Technologies Raises USD106.5 Million in Public Offering of Shares 26
DBV Technologies Raises USD34 Million in Private Placement of Shares 28
DBV Technologies Raises USD22.8 Million in Private Placement of Shares 30
DBV Technologies Completes IPO for USD53.6 Million 32
Stallergenes Acquires 2% Stake in DBV Technologies 34
DBV Technologies SA, Key Competitors 35
DBV Technologies SA, Key Employees 36
DBV Technologies SA, Other Locations 37
DBV Technologies SA, Subsidiaries 37

List of Figures
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DBV Technologies SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
DBV Technologies SA, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ DBV Technologies SA (DBV)：製薬・医療：M&Aディール及び事業提携情報(DBV Technologies SA (DBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • PeptiDream Inc (4587)：企業の財務・戦略的SWOT分析 Summary PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform that helps to produce peptide libraries for the identification of highly potent and selective hit candidates. Its technologies include flexizyme; translation, cyclization, and peptide modifying technologies; and PD display. PeptiDream’s technologies enables the production of peptide libraries for the development of peptide-based products. PeptiDreamoffers products for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, and others. The company collaborates with other biotechnology and drug development companies...
  • BioScrip Inc (BIOS)：企業の財務・戦略的SWOT分析 BioScrip Inc (BIOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s...
  • Xylem Inc (XYL)：石油・ガス：M&Aディール及び事業提携情報 Summary Xylem Inc (Xylem) is a water technology company. It designs, manufactures, and services engineered solutions ranging across a wide variety of applications. The company’s offerings address customer needs across the water cycle, from the delivery, measurement and use of drinking water to the collection, test and treatment of wastewater to the return of water to the environment. Xylem serves customers in water utilities, industrial, and utility infrastructure solutions and services sectors in North America, Europe, Asia Pacific, and other regions. It has manufacturing facilities in Sweden, the US, China, the UK, Italy, Poland, and the UAE. Xylem is headquartered...
  • Orchard Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報 Summary Orchard Therapeutics Ltd (Orchard) is an integrated commercial-stage biotechnology company that develops gene therapies for the treatment of serious and life-threatening orphan diseases. Its pipeline products include Strimvelis, an autologous ex vivo gammaretroviral gene therapy for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID); OTL-103 for Wiskott-Aldrich syndrome (WAS); OTL-102 for X-linked chronic granulomatous disease (X-CGD); OTL-300 for transfusion-dependent beta-thalassemia; and OTL-200 for metachromatic leukodystrophy (MLD), among others. The company works in partnership with institutions that specialize in gene and cell therapy such as The University of Manchester, Boston Children’s Hospital, and The San Raffaele Telethon Institute for...
  • Iberdrola SA (IBE)：電力：M&Aディール及び事業提携情報 Summary Iberdrola SA (Iberdrola) is an energy utility. It constructs, operates, and manages power generation plants, transmission and distribution facilities, and other assets. The company produces electricity using conventional and renewable energy sources. Iberdrola also trades electricity and gas in wholesale markets; and retails electricity, gas, and other related products and services. It retails energy to residential, commercial, industrial, institutional, and other customers. The company operates in Europe, North America, South America, and other regions. Iberdrola is headquartered in Bilbao, Vizcaya, Spain. Iberdrola SA (IBE) - Power - Deals and Alliances Profile provides you comprehensive data and trend analysis of...
  • Factor Therapeutics Ltd (FTT)-製薬・医療分野：企業M&A・提携分析 Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor which is being developed to treat venous leg ulcers. FTL offers cell culture reagents to enhance the growth of mammalian cells for cell-based therapies. The company’s VF-001 pursues the development of other product candidates which may be applicability to other wound care applications. It utilizes third parties for development and commercialization of its novel products. FTL...
    • ◆H&Iグローバルリサーチのお客様（例）◆